within Pharmacolibrary.Drugs.ATC.J;

model J01GB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.041666666666666664,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Netilmicin is a semisynthetic aminoglycoside antibiotic derived from sisomicin. It is used primarily for the treatment of serious infections caused by susceptible Gram-negative bacteria, such as urinary tract infections, respiratory tract infections, and sepsis. The drug has been largely replaced by other aminoglycosides or alternative antibiotics in many regions, but is still in use in some countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with normal renal function after intravenous administration.</p><h4>References</h4><ol><li><p>Welling, PG, et al., &amp; Madsen, PO (1977). Netilmicin pharmacokinetics after single intravenous doses to elderly male patients. <i>Antimicrobial agents and chemotherapy</i> 12(3) 328–334. DOI:<a href=&quot;https://doi.org/10.1128/AAC.12.3.328&quot;>10.1128/AAC.12.3.328</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/907325/&quot;>https://pubmed.ncbi.nlm.nih.gov/907325</a></p></li><li><p>Michalsen, H, &amp; Bergan, T (1981). Pharmacokinetics of netilmicin in children with and without cystic fibrosis. <i>Antimicrobial agents and chemotherapy</i> 19(6) 1029–1031. DOI:<a href=&quot;https://doi.org/10.1128/AAC.19.6.1029&quot;>10.1128/AAC.19.6.1029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7271272/&quot;>https://pubmed.ncbi.nlm.nih.gov/7271272</a></p></li><li><p>Jauregizar, N, et al., &amp; Calvo, R (2003). Population pharmacokinetics of netilmicin in short-term prophylactic treatment. <i>British journal of clinical pharmacology</i> 55(6) 552–559. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.2003.01783.x&quot;>10.1046/j.1365-2125.2003.01783.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12814449/&quot;>https://pubmed.ncbi.nlm.nih.gov/12814449</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01GB07;
